These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21438069)

  • 1. Budget allocation and the revealed social rate of time preference for health.
    Paulden M; Claxton K
    Health Econ; 2012 May; 21(5):612-8. PubMed ID: 21438069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discounting and decision making in the economic evaluation of health-care technologies.
    Claxton K; Paulden M; Gravelle H; Brouwer W; Culyer AJ
    Health Econ; 2011 Jan; 20(1):2-15. PubMed ID: 21154521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis.
    Schad M; John J
    Eur J Health Econ; 2012 Apr; 13(2):127-44. PubMed ID: 21170731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health economic decision-making: a comparison between UK and Spain.
    Corbacho B; Pinto-Prades JL
    Br Med Bull; 2012 Sep; 103(1):5-20. PubMed ID: 22833571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eliciting stated preferences for health-technology adoption criteria using paired comparisons and recommendation judgments.
    Johnson FR; Backhouse M
    Value Health; 2006; 9(5):303-11. PubMed ID: 16961548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane.
    Sendi PP; Briggs AH
    Health Econ; 2001 Oct; 10(7):675-80. PubMed ID: 11747050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions.
    McKenna C; Chalabi Z; Epstein D; Claxton K
    J Health Econ; 2010 Jan; 29(1):170-81. PubMed ID: 20018396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discounting in health care decision-making: time for a change?
    Sheldon TA
    J Public Health Med; 1992 Sep; 14(3):250-6. PubMed ID: 1419202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UK budgetary systems and new health-care technologies.
    McGuire A; Litt M
    Value Health; 2003; 6 Suppl 1():S64-73. PubMed ID: 12846927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discounting in economic evaluations: stepping forward towards optimal decision rules.
    Gravelle H; Brouwer W; Niessen L; Postma M; Rutten F
    Health Econ; 2007 Mar; 16(3):307-17. PubMed ID: 17006970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget impact analysis.
    Leelahavarong P
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S65-71. PubMed ID: 24964701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis and policy choices: investing in health systems.
    Murray CJ; Kreuser J; Whang W
    Bull World Health Organ; 1994; 72(4):663-74. PubMed ID: 7923545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
    Adang E; Voordijk L; Jan van der Wilt G; Ament A
    Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Portfolio theory and cost-effectiveness analysis: a further discussion.
    Sendi P; Al MJ; Rutten FF
    Value Health; 2004; 7(5):595-601. PubMed ID: 15367254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Participatory health system priority setting: Evidence from a budget experiment.
    Costa-Font J; Forns JR; Sato A
    Soc Sci Med; 2015 Dec; 146():182-90. PubMed ID: 26517295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
    Chiao E; Meyer K
    Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of budget impact in drug reimbursement decisions.
    Cohen JP; Stolk E; Niezen M
    J Health Polit Policy Law; 2008 Apr; 33(2):225-47. PubMed ID: 18325899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of cost-effectiveness analysis to multiple products: a practical guide.
    Bala MV; Zarkin GA
    Am J Manag Care; 2002 Mar; 8(3):211-8. PubMed ID: 11915971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.